Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). - Henderson,I.C.; Berry,D.; Demetri,G.; Cirrincione,C. (Proc ASCO, 1998)